Don't be fooled by headlines, revenue beat estimates, and earning EX one time items was 41 cents VS estimates of 29 Cents.
Are you stupid or what, you call under $300 million market cap, massive? Maybe you don't know what market cap means. didn't one biotech with no revenue just got bought out for $3.8 Billion?
This disease kills 48000 people in US alone, more than breast cancer, the pts population in US is 128000.
The drug price is at $42,000 in Canada and Europe. I think Goldman downgraded the stock to neutral to prevent it from going up too much to spoil the deal.
Tired of this man padding himself in back and telling how great they done, while running this company to ground. He is picking up what others want to throw away, and claims he can do better with the asets, well he is wrong, the joke has been on him. Sold the shares.
ENTA has very low market cap, and very rich pipeline in very hot areas. The analyst thinks because Abive is buying Shire they will not buy ENTA any more. Wrong, ENTA will be a small acquisition even at 100% premium. If economically makes sense , then Abive will buy, and it sure does make sense for Avive to buy this incredible value Biotech.
Insurance companies still cover drugs that are not in formulary, but copay is higher. So companies poorly worded press release that 20 to 30% is affected, does not mean they are going to lose 20-30 sales. affect on sales depends how bad the patients want the drug, and if they are willing to pay the higher copay.
This despite the fact that ENTA's drug is rear approval, and IDIX is in 2nd inning on their drug.
Company were assigned 2 companies as part of the contractor group. Allegations has been made that a senior Angolan government officials had interest in one of these contractors ( source 2013, 10K. Company claims that they did not know this company well, therefore they were not aware of the official interest.
From what I understand, in that part of the world, this is how cookie crumbles. The question is what is at stake for shareholders. From my point of view, you need to do a search on background of the companies you deal with, but is this sort of thing that is a routine practice in Angola, are the others doing it as well. This is important, I think CIE can easily handle the SEC fines, but what are the consequences in Angola, I suspect nothing, corruption is perhaps the way of the life, and expected there.
Cramer is at it again, cheer leading this dog, which has disappointed quarter after quarter. These depleted oil wells that they bought from Exxon, saying they were smarter than Exxon, are producing a lot of water, so much water that it has become disruptive. I think there is more disappointment to come. When you are not making money, and you have pilled up as much debt as these guys have for something that is not working, dividend would be eliminated before long.
Surely they would not owned that many share if conclusion such as contributor to SA could be reached with publicly available data could be reached, Fidelity would not have this many shares.
not $2.5 billion, $3.8 Billion, ENTA has a drug in verge of approval, and same valuation as IDIX will put ENTA at $200
Isis Pharmaceuticals Inc. (ISIS), a maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.
The drug targets the APOC3 gene and is now aimed solely at a rare disease that’s linked to diabetes and pancreatitis and affects about 5,000 people. Two studies this week, however, have also tied the gene to lower risk of heart disease, an illness that kills 600,000 people yearly, a much larger target.
The research, done independently of Isis, was highlighted in the New England Journal of Medicine. It may open a new window of opportunity for Isis once the drug, called ISIS-APOCIIIRx and heading to final testing, is approved and may spark interest from potential acquirers, analysts said.
“We’re weighing how we want to take full advantage of this breakthrough, and as we do that we have to consider the potential broader development of the follow on product,” Isis Chief Executive Officer Stanley Crooke said by telephone. “We have a great deal of licensing interest for this drug.”
In the New England Journal of Medicine studies, mutations in the APOC3 gene decreased the risk of a heart attack by about 40 percent. Adding value to the current drug could open the company up to a takeover bid, said Joshua Schimmer, a Piper Jaffray & Co. analyst in New York.
The Carlsbad, California-based company has “a super deep pipeline, and none of it is adequately reflected in the stock price,” Schimmer said in a telephone interview. “At this valuation, it would be ripe for a hostile event.”
Isis, founded by by Crooke in 1989, has grown to a $4.09 billion market capitalization and a pipeline of 32 products. Today the stock rose 3.2 percent to $34.82 at 4 p.m. New York time. It has dropped 41 percent since reaching a record high of $59 on February 21, compared with a 6.8 percent drop
I am not worried about inversion bill. Republicans will use this to push for lowering taxes on corporations, which is a double taxation on investors.
This sort of thing happen, but press release is making it worse. Investors would want to know what they will do so that this does not happen with others, and what they are going to do to get back on the formulary, was it a price issue, why they took them out?